| Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study. | |
| | |
MedLine Citation:
|
PMID: 19855268 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The physiopathology of levodopa-induced dyskinesias (LIDs) is unclear. Presynaptic pharmacokinetic and postsynaptic pharmacodynamic mechanisms may be involved. We have analyzed several clinical and pharmacological parameters, as well as the status of the presynaptic dopamine nigrostriatal pathway by using DaTSCAN, in 14 patients with Parkinson disease who developed early and severe LID despite using low doses of levodopa and 10 patients without this complication despite the use of high levodopa doses. Patients were matched for age at onset, duration, and severity of Parkinson disease. Statistically significant differences were observed only in the duration of LID during the levodopa challenge. However, clear differences were also observed in weight and sex distribution (women with low weight predominate in the group with dyskinesia), severity and duration of LID, and total levodopa dosage. The pattern of response to levodopa and the uptake of (123I)N-w-fluoropropyl-2[beta]-carbomethoxy-3[beta]-(4-iodophenyl)nortropane were similar in both groups. These results indicate that the development of LID needs additional contributions beyond nigrostriatal denervation. Factors related to sex and body weight could play an important role. However, these findings should be considered cautiously because of the limited statistical power of the study. |
| | |
Authors:
|
Gurutz Linazasoro; Nadege Van Blercom; Alberto Bergaretxe; Fernández Manchola Iñaki; Enrique Laborda; José Angel Ruiz Ortega |
Related Documents
:
|
1801538 - Monoamine oxidase, dopamine and parkinson's disease. 9322838 - High-frequency stimulation of the globus pallidus internalis in parkinson's disease: a ... 1584188 - Protective and preventive therapeutic strategies: monoamine oxidase inhibitors. 8656708 - Treatment of early parkinson's disease: are complicated strategies justified? 9408418 - Shall we wait until the head of the femur is completely crushed in idiopathic necrosis ... 18426548 - Assessment of disease named entity recognition on a corpus of annotated sentences. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical neuropharmacology Volume: 32 ISSN: 1537-162X ISO Abbreviation: Clin Neuropharmacol Publication Date: 2009 Nov-Dec |
Date Detail:
|
Created Date: 2009-12-07 Completed Date: 2010-02-25 Revised Date: 2011-02-16 |
Medline Journal Info:
|
Nlm Unique ID: 7607910 Medline TA: Clin Neuropharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 326-9 Citation Subset: IM |
Affiliation:
|
Centro Investigación Parkinson, Fundación Dr Carlos Elósegi, Policlínica Gipuzkoa, Parque Tecnológico de Miramón 174, San Sebastián, Spain. glinazasoro@terra.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Body Weight Dyskinesia, Drug-Induced / complications, physiopathology* Female Humans Levodopa / pharmacology* Male Parkinson Disease, Secondary / complications, physiopathology* Sex Factors Substantia Nigra / physiopathology* Tomography, Emission-Computed, Single-Photon / methods* |
| Chemical | |
Reg. No./Substance:
|
0/Levodopa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects...
Next Document: High-sensitivity C-reactive protein and plaque composition in patients with stable angina pectoris: ...